Evidence map›Paper›PMID 26858184›Full record

ArticleEndocrine2016

Minimally invasive follicular thyroid carcinomas: prognostic factors.

Gustav Stenson, Inga-Lena Nilsson, Ninni Mu, Catharina Larsson, Catharina Ihre Lundgren, C Christofer Juhlin, Anders Höög, Jan Zedenius

Open access · hybridAbstract read
In one paragraph

Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gustav StensonDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Stockholm, Sweden.
Inga-Lena NilssonDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Stockholm, Sweden. inga-lena.nilsson@ki.se.ORCID http://orcid.org/0000-0002-8966-3729
Ninni MuDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Stockholm, Sweden.
Catharina LarssonDepartment of Oncology-Pathology, Karolinska Institutet, CCK, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Catharina Ihre LundgrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Stockholm, Sweden.
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, CCK, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Anders HöögDepartment of Oncology-Pathology, Karolinska Institutet, CCK, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Jan ZedeniusDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SESophiahemmet Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although minimally invasive follicular thyroid carcinoma (MI-FTC) is regarded as an indolent tumour, treatment strategies remain controversial. Our aim was to investigate the outcome for patients with MI-FTC and to identify prognostic parameters to facilitate adequate treatment and follow-up. This retrospective follow-up study involved all cases of MI-FTC operated at the Karolinska University Hospital between 1986 and 2009. Outcome was analysed using death from MI-FTC as endpoint. Fifty-eight patients (41 women and 17 men) with MI-FTC were identified. The median follow-up time was 140 (range 21-308) months. Vascular invasion was observed in 36 cases and was associated with larger tumour size [median 40 (20-76) compared with 24 (10-80) mm for patients with capsular invasion only (P = 0.001)] and older patients [54 (20-92) vs. 44 (11-77) years; P = 0.019]. Patients with vascular invasion were more often treated with thyroidectomy (21/36 compared to 7/22 with capsular invasion only; P = 0.045). Five patients died from metastatic disease of FTC after a median follow-up of 114 (range 41-193) months; all were older than 50 years (51-72) at the time of the initial surgery; vascular invasion was present in all tumours and all but one were treated with thyroidectomy. Univariate analysis identified combined capsular and vascular invasion (P = 0.034), age at surgery ≥50 years (P = 0.023) and male gender (P = 0.005) as related to risk of death from MI-FTC. MI-FTC should not be considered a purely indolent disease. Age at diagnosis and the existence of combined capsular and vascular invasion were identified as important prognostic factors.

Indexed as

Adenocarcinoma, FollicularAdolescentAdultAgedAged, 80 and overAge FactorsChildFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeovascularization, PathologicPrognosisRetrospective StudiesCarcinomaFollicularMinimally invasivePrognosisThyroid

Identifiers

PMID26858184
PMCPMC4949299
OpenAlexW2263130236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.